Epistem Holdings Plc, the biotechnology and personalised medicine company, announced an agreement to raise £2.8 million via a placing at 350p per share in exchange for shares representing 9.1% of the enlarged share capital. The funds will be used to accelerate the development and commercialisation of Genedrive.
The EHP share price has decreased by 10% over the last year.
Epistem Holdings Plc is currently graded b by LCF Research. To learn more, follow the link.
